Author:
Littmann Jasper,Rid Annette,Buyx Alena
Abstract
Abstract
To reduce the effect of antimicrobial resistance and preserve antibiotic effectiveness, clinical practice guidelines and health policy documents call for the “rational use” of antibiotics that aims to avoid unnecessary or minimally effective antibiotic prescriptions. In this paper, we show that rational use programmes can lead to ethical conflicts because they place some patients at risk of harm – for example, a delayed switch to second-line antibiotics for community-acquired pneumonia is associated with increased fatality rates. Implementing the rational use of antibiotics can therefore lead to conflicts between promoting patients’ clinical interests and preserving antibiotic effectiveness for future use. The resulting ethical dilemma for clinicians, patients and policy makers has so far not been adequately addressed. We argue that existing guidance for acceptable risks in clinical research can help to define risk thresholds for the rational use of antibiotics. We develop an ethical framework that allows clinicians and policy-makers to evaluate policies for rational antibiotic use in six practical steps.
Publisher
Springer International Publishing
Reference56 articles.
1. Adeyi, O. et al. 2017. Drug-resistant infections: A threat to our economic future (vol. 2): final report. Washington, DC. World Bank Group.
http://documents.worldbank.org/curated/en/323311493396993758/final-report
.
2. Andreasen, M. 2014. Arbejdspapirer om antibiotikaresistens (Working papers on antibiotic resistance). Det Etiske Råd (Danish Ethics Council): Copenhagen.
3. Australian Department of Health. 2015. Responding to the threat of antimicrobial resistance: Australia’s first national antimicrobial resistance strategy 2015–2019. Canberra.
4. Battin, M.P., L.P. Francis, J.A. Jacobson, et al. 2009. The patient as victim and vector: Ethics and infectious disease. New York: Oxford University Press.
5. Boucher, H.W., G.H. Talbot, D.K. Benjamin, et al. 2013. 10 × ‘20 Progress—Development of new drugs active against gram-negative bacilli: An update from the Infectious Diseases Society of America. Clinical Infectious Diseases 56: 1685–1694.